Tolazamide (Standard)
Tolazamide (U-17835) (Standard) is the analytical standard of Tolazamide. This product is intended for research and analytical applications. Tolazamide is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98%
- CAS No.: 1156-19-0
- Formule: C14H21N3O3S
- Masse moléculaire:311.40
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 1156-19-0
-
Masse moléculaire 311.40
-
Formule C14H21N3O3S
-
SMILES
O=S(C1=CC=C(C)C=C1)(NC(NN2CCCCCC2)=O)=O
-
Synonyms
U-17835 (Standard)
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[2]. Gopalakrishnan, M., et al., (2000). Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. British journal of pharmacology, 129(7), 1323–1332. [Content Brief]
[3]. Kabadi U. M. (1985). Adjuvant therapy with tolazamide and insulin improves metabolic control in type I diabetes mellitus. Diabetes care, 8(5), 440–446. [Content Brief]
[4]. McCormick, K., et al., (1986). Effect of tolazamide on basal ketogenesis, glycogenesis, and gluconeogenesis in liver obtained from normal and diabetic rats. Endocrinology, 119(3), 1268–1273. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tolazamide (Standard) Related Classifications
HY-B0920R Related Classifications
Powered by Bioz